Compugen Ltd. (CGEN)

2,1300 -0,0800 (-3,62 %) À la clôture : 04:00PM EDT

Compugen Ltd.

Azrieli Center
Building D 26 Harokmim Street
Holon 5885849
Israel
972 3 765 8585
https://cgen.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 68

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Anat Cohen-Dayag Ph.D.	CEO, President & Director	796,52k	S.O.	1967
Dr. Zurit Levine Ph.D.	Senior Vice President of Technology Innovation	345,7k	S.O.	1968
Dr. Pierre Ferre Ph.D.	Vice President of Preclinical Development	415,1k	S.O.	1977
Mr. Alberto Sessa	Chief Financial Officer	S.O.	S.O.	1962
Dr. Eran Ophir Ph.D.	Chief Scientific Officer	S.O.	S.O.	1978
Ms. Yvonne Naughton	Head of Investor Relations & Corporate Communications	S.O.	S.O.	S.O.
Mr. Eran Ben Dor	General Counsel & Corporate Secretary	S.O.	S.O.	S.O.
Ms. Dorit Amitay	Vice President of Human Resources	S.O.	S.O.	1968
Dr. Yaron Turpaz M.B.A., Ph.D.	Senior VP & Senior Advisor of Data and Informatics Solutions	S.O.	S.O.	1971
Rivka Schwartz	Vice President Research and Discovery	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Compugen Ltd. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.